Propulsion of Acute Lymphocytic Leukemia Pipeline as Novel and Extensive 160+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

New York, USA, March 30, 2023 (GLOBE NEWSWIRE) — Propulsion of Acute Lymphocytic Leukemia Pipeline as Novel and Extensive 160+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

The prevalence of acute lymphocytic leukemia has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Acute Lymphocytic Leukemia and the growing research and development activities to develop novel therapies to treat acute lymphocytic leukemia to drive the market. The companies developing the potential therapies in the last stage of development include Juventas Cell Therapy, AbbVie, Janssen Biotech, and several others.

DelveInsight’s ‘Acute Lymphocytic Leukemia Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline acute lymphocytic leukemia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the acute lymphocytic leukemia pipeline domain.

Key Takeaways from the Acute Lymphocytic Leukemia Pipeline Report

• DelveInsight’s acute lymphocytic leukemia pipeline report depicts a robust space with 150+ active players working to develop 160+ pipeline therapies for acute lymphocytic leukemia treatment. 
• Key acute lymphocytic leukemia companies such as PersonGen BioTherapeutics, Takara Bio Inc., Cellectis S.A., AbbVie, Autolus Limited, Juventas Cell Therapy Ltd., Orca Biosystems, Inc., Sanofi, Beijing Immunochina Medical Science & Technology Co., Ltd., Actinium Pharmaceuticals, Nanjing Bioheng Biotech Co., Ltd., Legend Biotech, Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Kymera Therapeutics, PeproMene Bio, Inc., Takeda Oncology, OneChain Immunotherapeutics, JW Therapeutics, Jazz Pharmaceuticals, Novartis, BRL Medicine, Meryx, Inc.,  Syndax Pharmaceuticals, Janssen Research & Development, LLC, Daiichi Sankyo Company, SecuraBio, Fate Therapeutics, In8bio Inc.,  Newave Pharmaceutical Inc, AstraZeneca,  Biomea Fusion Inc., Karyopharm Therapeutics Inc, Nkarta Inc., Athenex, Inc., ERYtech Pharma, Chongqing Precision Biotech Co., Ltd, Incyte Corporation, BioLineRx, Ltd, OSE Immunotherapeutics, Aleta Biotherapeutics, CalciMedica, Inc., Cabaletta Bio, Hebei Senlang Biotechnology, and others are evaluating new acute lymphocytic leukemia drugs to improve the treatment landscape.
• Promising acute lymphocytic leukemia pipeline therapies such as CD7 CAR-T cells infusion, TBI-1501, UCART22, Navitoclax, AUTO1, CNCT19, Orca-T, SAR443579, IM19 CAR-T cells, 131-I Apamistamab, CTA30X, CT-RD06, LCAR-AIO Cells, GNC-038, KT-253, BAFFR-CAR T cells, Pevonedistat, OC-1, OC-2, Carteyva, CPX-351, ABL001,  BRL 301, MRX-2843, PIT565, SNDX-5613, JNJ-75276617, AC220, Duvelisib, FT819, EAGD T-cell infusion, LP-108, AZD4573, LP-118, BMF-219, KPT-330, NKX019, KUR-502,  GRASPA, pCAR-19B cells, Ruxolitinib, BL-8040,  OSE-127, WU CART 007, ALETA 001, CM4620,  CT120, CD123, SENL-B-19, SENL 101, HY004,  and others are under different phases of acute lymphocytic leukemia clinical trials.
• In February 2023, OSE Immunotherapeutics SA announced the online publication in the peer-reviewed ‘The Journal of Immunology’ of positive Phase I clinical results with OSE-127/S95011, an anti-IL-7 receptor (IL-7R) antagonist, and provides an overall update on the product, which is being developed in immuno-inflammation through two ongoing Phase II clinical trials in Ulcerative Colitis (sponsor OSE) and in primary Sjögren’s Syndrome (sponsor Servier), and in hematology where promising preclinical data in Acute Lymphoblastic Leukemia (ALL) has already been reported.OSE-127 has also demonstrated great therapeutic potential in Acute Lymphoblastic Leukemia (ALL), a very aggressive tumor arising from B or T cell precursors. 
• In December 2022, Juventas Cell Therapy, announced that Inaticabtagene Autoleucel (CNCT19 Injection) has been granted Priority Review Status by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) to the New Drug Application (NDA) acceptance, for the treatment of adult relapsed and refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
• In December 2022, Juventas Cell Therapy, announced that the National Medical Product Administration (NMPA) of China has accepted the New Drug Application (NDA) of Inaticabtagene Autoleucel (CNCT19 Injection) for the treatment of adult relapsed and refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
• In July 2022, the FDA granted fast-track and rare pediatric disease designations to the CAR T-cell therapy WU-CART-007 for the treatment of patients with relapsed/refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) and lymphoblastic lymphoma (LBL).WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR T-cell therapy. The product is designed to overcome the technological challenges of harnessing CAR-T cells to treat CD7-positive hematological malignancies.
• In May 2022, The FDA granted regenerative medicine advanced therapy designation to obecabatagene autoleucel for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Obecabatagene autoleucel also referred to as obe-cel, is an autologous, gene-edited chimeric antigen receptor T-cell therapy that targets the CD19 protein on the surface of cancer cells.
• In November 2021, Autolus Therapeutics plc and Blackstone Life Sciences announced that the two companies have entered into a strategic collaboration and financing agreement under which funds managed by Blackstone will provide up to $250 million in equity and product financing to support Autolus’ advancement of its CD19 CAR T cell investigational therapy product candidate, obecabtagene autoleucel (obe-cel), as well as next generation product therapies of obe-cel in B-cell malignancies.

Request a sample and discover the recent advances in acute lymphocytic leukemia treatment drugs @ Acute Lymphocytic Leukemia Pipeline Report

The acute lymphocytic leukemia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage acute lymphocytic leukemia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the acute lymphocytic leukemia clinical trial landscape.

Acute Lymphocytic Leukemia Overview

Acute lymphocytic leukemia (ALL) is also known as acute lymphoblastic leukemia. ALL begins in the bone marrow (the soft inner part of certain bones, where new blood cells are made). Most leukemia cells invade the blood fairly quickly. They can also spread to other body parts, such as the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles (in males). Some cancers can begin in these organs and spread to the bone marrow, but these are not leukemia.

The early signs and acute lymphocytic leukemia symptoms may resemble those of the flu or other common diseases. Some common signs and acute lymphocytic leukemia symptoms are weakness or tiredness, fever or drenching night sweats, easy bruising or bleeding, shortness of breath, weight loss or loss of appetite, and others.

The tests used for acute lymphocytic leukemia diagnosis include physical exam and health history, complete blood count (CBC) with differential, bone marrow aspiration, and biopsy. The standard goal of acute lymphocytic leukemia includes chemotherapy, radiation therapy, chemotherapy with stem cell transplant, and targeted therapy.

Find out more about acute lymphocytic leukemia treatment drugs @ Drugs for Acute Lymphocytic Leukemia Treatment

A snapshot of the Acute Lymphocytic Leukemia Pipeline Drugs mentioned in the report:

Learn more about the emerging acute lymphocytic leukemia pipeline therapies @ Acute Lymphocytic Leukemia Clinical Trials

Acute Lymphocytic Leukemia Therapeutics Assessment

The acute lymphocytic leukemia pipeline report proffers an integral view of the acute lymphocytic leukemia emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Acute Lymphocytic Leukemia Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Infusion, Intradermal, Intramuscular, Intranasal, Intravenous, Oral, Parenteral, Subcutaneous
• Therapeutics Assessment By Molecule Type: Gene therapies, Small molecule, Vaccines, Polymers, Peptides, Monoclonal antibodies
• Therapeutics Assessment By Mechanism of Action: Antimetabolites, DNA intercalators, DNA synthesis inhibitors, Type II DNA topoisomerase inhibitors, Immunologic cytotoxicity, T lymphocyte replacements, Apoptosis stimulants, Proto-oncogene protein c-bcl-2 inhibitors
• Key Acute Lymphocytic Leukemia Companies: PersonGen BioTherapeutics, Takara Bio Inc., Cellectis S.A., AbbVie, Autolus Limited, Juventas Cell Therapy Ltd., Orca Biosystems, Inc., Sanofi, Beijing Immunochina Medical Science & Technology Co., Ltd., Actinium Pharmaceuticals, Nanjing Bioheng Biotech Co., Ltd., Legend Biotech, Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Kymera Therapeutics, PeproMene Bio, Inc., Takeda Oncology, OneChain Immunotherapeutics, JW Therapeutics, Jazz Pharmaceuticals, Novartis, BRL Medicine, Meryx, Inc.,  Syndax Pharmaceuticals, Janssen Research & Development, LLC, Daiichi Sankyo Company, SecuraBio, Fate Therapeutics, In8bio Inc.,  Newave Pharmaceutical Inc, AstraZeneca,  Biomea Fusion Inc., Karyopharm Therapeutics Inc, Nkarta Inc., Athenex, Inc., ERYtech Pharma, Chongqing Precision Biotech Co., Ltd, Incyte Corporation, BioLineRx, Ltd, OSE Immunotherapeutics, Aleta Biotherapeutics, CalciMedica, Inc., Cabaletta Bio, Hebei Senlang Biotechnology, and others
• Key Acute Lymphocytic Leukemia Pipeline Therapies: CD7 CAR-T cells infusion, TBI-1501, UCART22, Navitoclax, AUTO1, CNCT19, Orca-T, SAR443579, IM19 CAR-T cells, 131-I Apamistamab, CTA30X, CT-RD06, LCAR-AIO Cells, GNC-038, KT-253, BAFFR-CAR T cells, Pevonedistat, OC-1, OC-2, Carteyva, CPX-351, ABL001,  BRL 301, MRX-2843, PIT565, SNDX-5613, JNJ-75276617, AC220, Duvelisib, FT819, EAGD T-cell infusion, LP-108, AZD4573, LP-118, BMF-219, KPT-330, NKX019, KUR-502,  GRASPA, pCAR-19B cells, Ruxolitinib, BL-8040,  OSE-127, WU CART 007, ALETA 001, CM4620,  CT120, CD123, SENL-B-19, SENL 101, HY004, and others

Dive deep into rich insights for new drugs for acute lymphocytic leukemia treatment, visit @ Acute Lymphocytic Leukemia Drugs

Table of Contents

For further information on the Acute Lymphocytic Leukemia pipeline therapeutics, reach out @ Acute Lymphocytic Leukemia Treatment Drugs

Related Reports

Acute Lymphocytic Leukemia Epidemiology

Acute Lymphocytic Leukemia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted acute lymphocytic leukemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Acute Lymphocytic Leukemia Market

Acute Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key acute lymphocytic leukemia companies, including AbbVie, Autolus Limited, Juventas Cell Therapy Ltd., Pinze Lifetechnology Co. Ltd., Celgene, among others.

Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute myeloid leukemia companies, including Takeda Oncology, Immunity Bio, Teva Pharmaceuticals, among others.

Acute Myeloid Leukemia Pipeline

Acute Myeloid Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute myeloid leukemia companies, including Takeda Oncology, Immunity Bio, Teva Pharmaceuticals, among others.

Chronic Lymphocytic Leukemia Pipeline

Chronic Lymphocytic Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic lymphocytic leukemia companies, including Celgene, Loxo Oncology, Octapharma, among others.

Chronic Myeloid Leukemia Pipeline

Chronic Myeloid Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic myeloid leukemia companies, including Kartos Therapeutics, Novartis, Incyte Corporation, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market 

Related Healthcare Blogs 

Upcoming Oncology Drugs

Oncology Market Outlook

Future of Oncology Market

Related Cases Studies

Competitive Intelligence

Market Assessment

Product Assessment

Epidemiology Assessment

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn